Go Pro
NASDAQ:ZLAB

Zai Lab Q1 2026 Earnings Report

Zai Lab logo
$25.69 +0.71 (+2.84%)
Closing price 04:00 PM Eastern
Extended Trading
$25.69 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zai Lab EPS Results

Actual EPS
-$0.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Zai Lab Revenue Results

Actual Revenue
$99.61 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zai Lab Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zai Lab's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Zai Lab Earnings Headlines

Zai Lab (NASDAQ:ZLAB) Stock Bumped Up to "Hold" by Wall Street Zen
Zai Lab Ltd (ZLAB)
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.tc pixel
Zai Lab Limited (ZLAB)
See More Zai Lab Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zai Lab? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zai Lab and other key companies, straight to your email.

About Zai Lab

Zai Lab (NASDAQ:ZLAB) Limited is a biopharmaceutical company focused on discovering, developing and commercializing medicines for significant unmet medical needs. The company’s research and development activities have centered on oncology, autoimmune and inflammatory diseases, infectious diseases, and neuroscience. Zai Lab operates through a combination of internally developed programs and collaborations with global pharmaceutical and biotechnology companies.

The company has built a commercial portfolio in Greater China that has included ZEJULA (niraparib), a PARP inhibitor used in certain ovarian cancer settings; QINLOCK (ripretinib), a treatment for gastrointestinal stromal tumors; and NUZYRA (omadacycline), an antibiotic for certain bacterial infections. Zai Lab has also advanced and commercialized additional partnered therapies in China and maintains a pipeline of investigational medicines across its core therapeutic areas.

Founded in 2014, Zai Lab is headquartered in Shanghai and has operations in China, the United States and other international markets. The company was founded by Samantha Du, who has served as its chief executive officer and has led its strategy of developing a globally oriented biopharmaceutical business with a focus on bringing innovative treatments to patients in China and other regions.

View Zai Lab Profile